Search hospitals > North Carolina > Greensboro
Cone Health Cancer Center
Claim this profileGreensboro, North Carolina 27403
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
171 reported clinical trials
3 medical researchers
Summary
Cone Health Cancer Center is a medical facility located in Greensboro, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Cone Health Cancer Center is involved with conducting 171 clinical trials across 191 conditions. There are 3 research doctors associated with this hospital, such as Vinay K. Gudena, Sarah E. Squire, and Ni Gorsuch.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Vinay K. GudenaCone Health Cancer Center1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
31 reported clinical trials
67 drugs studied
Sarah E. SquireCone Health Cancer Center5 years of reported clinical research
Studies Brain Tumor
Studies Cancer
1 reported clinical trial
3 drugs studied
Ni GorsuchCone Health Cancer Center4 years of reported clinical research
Studies Endometrial Cancer
Studies Endometrioid Carcinoma
1 reported clinical trial
3 drugs studied
Clinical Trials running at Cone Health Cancer Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Recurrence
Brain Tumor
ALK Gene Rearrangement
Cognitive Impairment
Peripheral Neuropathy
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Online Sexual Health Program
for Breast Cancer Survivors
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns. This study is being done to find out if the study approach is better or worse than the usual approach to helping breast cancer survivors manage cancer-related sexual concerns. The usual approach is defined as care most cancer survivors get for their cancer-related sexual concerns. Participants will complete a questionnaire and if they qualify, they will be assigned to one of sixteen groups of participants. Groups will get access to various kinds of help through an Internet-delivered program called SHINE, which was designed and is run by researchers at the University of Virginia Center for Behavioral Health and Technology. All groups will get access to education about sexual health after cancer: either a standard education website or an enhanced education web program. Groups may also receive up to three additional web programs on: talking to your clinicians about sexual concerns, and/or talking to your partner about sexual concerns, and/or increasing intimacy. Participants are asked to complete the SHINE program within 12 weeks. After participants finish this 12-week period, the study team will ask them to complete a questionnaire to check in with the participant. The participant will be asked one additional time 12 weeks later to complete another questionnaire to see how the participant is doing. A participant will be in the study for 24 weeks.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cone Health Cancer Center?
Cone Health Cancer Center is a medical facility located in Greensboro, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Cone Health Cancer Center is involved with conducting 171 clinical trials across 191 conditions. There are 3 research doctors associated with this hospital, such as Vinay K. Gudena, Sarah E. Squire, and Ni Gorsuch.